A Phase II, Multicenter, Double-blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Natalizumab (300 mg) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Receiving Concomitant Treatment With Methotrexate (MTX)
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Natalizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Biogen
- 09 Jun 2009 Primary endpoint identified as American College of Rheumatology 20 as reported by ClinicalTrials.gov.
- 09 Jun 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 15 Feb 2007 Status change